YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
|
Citation:
|
YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
|
YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
|
Citation:
|
YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
|
DownLoad: